News
-
-
-
-
PRESS RELEASE
Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
Spexis receives second extension from SIX Exchange Regulation AG to publish its 2023 annual report by July 31, 2024, providing unaudited financial statements and an update on the dispute with SPRIM -
-
PRESS RELEASE
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.
Spexis AG receives approval to extend deadline for publishing 2023 annual report and audited financials until May 31, 2024, due to ongoing legal discussions and negotiations with creditors -
-
PRESS RELEASE
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
Spexis AG extends moratorium and receives payment for antibiotics program sale while reverting lonodelestat license from Santhera -
PRESS RELEASE
Spexis announces closing of sale of preclinical antibiotics program to Basilea
Spexis AG announces the closing of the sale of a preclinical antibiotics program to Basilea, which will pay up to CHF 2 million for the program. The program targets Gram-negative bacteria, including multidrug-resistant strains. The sale is part of Spexis' strategy to divest non-core programs and assets to focus on rare diseases and oncology -
![Accesswire](/assets/images/accesswire-inline.png)
-
APWG 2024 Cybercrime Research Conference Extends Submission Deadline to July 7
-
Product Creation Studio Partners With PatchClamp Medtech Inc. to Develop Revolutionary Dural Repair System
-
XS Financial Enters Into Definitive Agreement to Be Taken Private
-
TRU Engages Investor Relations Specialists HE Capital Markets
-
DuJour Media Jason Binn Celebrates Successful 12th Anniversary Cover Party with Star-Studded After-Party and Record Turnout
![EQS Group](/assets/images/eqs-group.png)
-
Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
-
HORNBACH Group delivers strong Q1 2024/25 results increasing earnings per share y-o-y by 44% – full-year outlook confirmed unchanged
-
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
-
Meyer Burger makes significant progress in relocating its core business to the USA
-
BIRKENSTOCK ANNOUNCES LAUNCH OF SECONDARY OFFERING
![Les Echos](/assets/images/les-echos.png)
-
Schneider Electric launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 for a nominal amount of €750 million and a concurrent repurchase of its outstanding OCEANEs due 2026
-
Gimv increases its stake in TINC – Gimv and Belfius conclude agreement in principle on the sale of the shares of Belfius Insurance in TINC
-
Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2024
-
2023/2024 Third Quarter Sales
-
Disclosure of trading in own shares from June 17th, 2024, to June 21th, 2024. Detailed information per transaction